Back

Effect of diuretic dose on baxdrostat efficacy and safety in uncontrolled and resistant hypertension: a post hoc analysis of the BaxHTN trial

30 August 2026 (09:09 - 09:27)
Organised by: Logo
Congress Presentation Part of: New therapeutic strategies targeting renin-angiotensin-aldosterone system in hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Bryan Williams

University College London, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on new therapeutic strategies targeting renin-angiotensin-aldosterone system in hypertension
Professor C. Granger (Durham, US)
Slides Video
Presentation thumbnail
RNA interference therapy targeting hepatic angiotensinogen for the treatment of hypertension and cardiovascular disease: a first-in-human and proof-of-concept study
Doctor Y. He (US) Doctor C. O'Donnell (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of a novel low-dose triple combination antihypertensive pill on blood pressure, according to background blood pressure medications: results from the TRIDENT trial
Professor A. Rodgers (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Adherence to antihypertensive therapy and cardiovascular outcomes: an individual participant data meta-analysis of randomised controlled trials
Miss Q. Yang (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
New therapeutic strategies targeting renin-angiotensin-aldosterone system in hypertension
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 09:09 CET
You may be interested in
thumbnail
Congress Presentation
BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension
30 August 2025
thumbnail
Congress Session
Challenges in hypertension management
26 August 2023
thumbnail
Congress Presentation
AIMHY-INFORM: Dual Therapy Arm
29 August 2025
thumbnail
Congress Presentation
Low dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: the BARACK-D randomised trial
1 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources